Atypical Hemolytic Uremic Syndrome
Conditions
Brief summary
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
Interventions
DRUGCrovalimab
Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
Sponsors
Hoffmann-La Roche
Chugai Pharmaceutical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Body weight \>= 40 kg at screening. * Vaccination against Neisseria meningitidis serotypes A, C, W, and Y; vaccination against serotypes B, according to national vaccination recommendations. * Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations. * For participants continuing to receive other therapies concomitantly with crovalimab (e.g., immunosuppressants, corticosteroids, mammalian target of rapamycin inhibitor (mTORi) , or calcineurin inhibitors): stable dose for \>=28 days prior to screening and up to the first crovalimab administration. * For female participants of childbearing potential: an agreement to remain abstinent or use contraception. * Female participants of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of crovalimab. * Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant. * Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only). * Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only). * Clinical evidence of response to a C5 inhibitor (for Switch Cohort only). * Known C5 polymorphism (for C5 SNP Cohort only). * Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP Cohort only).
Exclusion criteria
* TMA associated with non-aHUS related renal disease. * Positive direct Coombs test. * Chronic dialysis within 90 days prior to first crovalimab administration and/or end stage renal disease. * Identified drug exposure-related TMA. * Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease. * History of a kidney disease, other than aHUS. * History of Neisseria meningitidis infection within 6 months of study enrollment. * Known or suspected immune deficiency (e.g., history of frequent recurrent infections). * Positive Human Immunodeficiency Virus (HIV) test. * Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration * Presence of fever (\>= 38°C) * Multi-system organ dysfunction or failure. * Recent intravenous immunoglobulin (IVIg) treatment. * Pregnant or breastfeeding or intending to become pregnant. * Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater. * Recent use of tranexamic acid. * Current or previous treatment with a complement inhibitor (for Naive Cohort only). * First initiation of plasma exchange/plasma infusions (PE/PI) should not be more than 28 days prior to first crovalimab administration (for Naive Cohort only). * Last PE/PI completed less than 2 hours prior to first crovalimab administration (for Naive Chorot only). * Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only). * Positive for active Hepatitis B and C infection (HBV/HCV) (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment). * Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment). * Diagnosis of condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC) * TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to a known DGKE nephropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants with Complete Thormbotic Microangiopathy Response (cTMAr) | Baseline up to Week 25 (after 24 weeks on treatment) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observed Value in Hemoglobin | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Change from Baseline in Platelet Count | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Change from Baseline in Lactate Dehydrogenase (LDH) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Change from Baseline in Hemoglobin | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Change from Baseline in Dialysis Status | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Percentage of Participants with Change from Baseline in Chronic Kidney Disease (CKD) Stage | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Observed Value in Platelet Count | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Mean Change From Baseline in Fatigue (in Adult Participants only) | Baseline up to Week 25 (after 24 weeks on treatment) | Assessed by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Questionnaire. The FACIT-Fatigue (version 4) assesses self-reported fatigue and its impact upon daily activities and function. It consists of 13 items that assess fatigue using a 7-day recall period. Items are scored on a 0 (not at all) to 4 (very much) response scale. Relevant items are reverse scored and all items are summed to create total scores ranging from 0 \[worse score\] to 52 \[better score\]. |
| Percentage of Participants with Platelet Count >= Lower Limits of Normal (LLN) (Naive Cohort only) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Percentage of Participants with Normalization of LDH (i.e. =< Upper Limit of Normal (ULN)) (Naive Cohort only) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Percentage of Participants with >=25% Decrease in Serum Creatinine (Naive Cohort only) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Time to cTMAr (Naive Cohort only) | Up to 8 years | — |
| Duration of cTMAr (Naive Cohort only) | Up to 8 years | — |
| Percentage of Participants with Ongoing cTMAr (Naive Cohort only) | At Week 25 | — |
| Percentage of Participants with Maintained Thrombotic Microangiopathy Control (mTMAc) (Switch Cohort only) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Percentage of Participants with Adverse Events (AEs) | Up to 8 years | — |
| Percentage of Participants with Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (Including Malignant Renal Hypertension) and Infections (Including Meningococcal Meningitis) | Up to 8 years | — |
| Number of Participants with AEs Leading to Study Drug Discontinuation | Up to 8 years | — |
| Percentage of Participants with Clinical Manifestations of Drug-Target-Drug Complex (DTDC) Formation Amongst Those Participants who Switched to Crovalimab Treatment From Eculizumab Treatment or Ravulizumab Treatment | Up to Week 25 | — |
| Serum Concentrations of Crovalimab Over Time | Up to 8 years | — |
| Prevalence of Anti-Crovalimab Antibodies at Baseline | Baseline | — |
| Percentage of Participants with Anti-Crovalimab Antibodies | Up to 8 years | — |
| Observed Value in Lactate Dehydrogenase (LDH) | Baseline up to Week 25 (after 24 weeks on treatment) | — |
| Observed value of Pharmacodynamic Markers (CH50, Free/Total C5) | Up to 8 years | — |
Countries
Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan, Mexico, Poland, Spain, Turkey (Türkiye), United States
Contacts
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed